{"fetched":"2026-09-09","source":"https://api.openalex.org/works","license":"CC0","papers":{"paper-alphafold2-jumper-nature-2021":{"doi":"10.1038/s41586-021-03819-2","openalexId":"W3177828909","cited":47111,"byYear":{"2012":7,"2013":4,"2014":1,"2017":2,"2019":2,"2020":19,"2021":1122,"2022":6494,"2023":9978,"2024":11955,"2025":11047,"2026":6449},"year":2021,"title":"Highly accurate protein structure prediction with AlphaFold"},"paper-hodi-ipilimumab-melanoma-nejm-2010":{"doi":"10.1056/nejmoa1003466","openalexId":"W2097995306","cited":15282,"byYear":{"2012":695,"2013":896,"2014":1026,"2015":1265,"2016":1260,"2017":1289,"2018":1217,"2019":1102,"2020":1191,"2021":1175,"2022":906,"2023":918,"2024":798,"2025":589,"2026":345},"year":2010,"title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma"},"paper-hallmarks-new-dimensions-cancer-discov-2022":{"doi":"10.1158/2159-8290.cd-21-1059","openalexId":"W4206662285","cited":9668,"byYear":{"2019":1,"2021":4,"2022":1014,"2023":2042,"2024":2711,"2025":2344,"2026":1550},"year":2022,"title":"Hallmarks of Cancer: New Dimensions"},"paper-vogelstein-cancer-genome-landscapes-science-2013":{"doi":"10.1126/science.1235122","openalexId":"W2044433401","cited":8142,"byYear":{"2012":2,"2013":198,"2014":541,"2015":682,"2016":720,"2017":778,"2018":751,"2019":708,"2020":682,"2021":671,"2022":682,"2023":515,"2024":513,"2025":406,"2026":275},"year":2013,"title":"Cancer Genome Landscapes"},"paper-gerlinger-intratumour-heterogeneity-nejm-2012":{"doi":"10.1056/nejmoa1113205","openalexId":"W2150575159","cited":7896,"byYear":{"2012":328,"2013":628,"2014":682,"2015":697,"2016":741,"2017":677,"2018":647,"2019":550,"2020":562,"2021":597,"2022":539,"2023":368,"2024":318,"2025":299,"2026":240},"year":2012,"title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing"},"paper-imbrave150-nejm-2020":{"doi":"10.1056/nejmoa1915745","openalexId":"W3025022288","cited":7490,"byYear":{"2014":1,"2016":2,"2019":1,"2020":296,"2021":1040,"2022":1296,"2023":1373,"2024":1352,"2025":1263,"2026":856},"year":2020,"title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma"},"paper-eliana-tisagenlecleucel-nejm-2018":{"doi":"10.1056/nejmoa1709866","openalexId":"W2787301955","cited":5792,"byYear":{"2012":1,"2013":1,"2018":242,"2019":496,"2020":719,"2021":812,"2022":809,"2023":762,"2024":786,"2025":676,"2026":477},"year":2018,"title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia"},"paper-flaura-nejm-2018":{"doi":"10.1056/nejmoa1713137","openalexId":"W2770828094","cited":5447,"byYear":{"2016":2,"2017":8,"2018":278,"2019":537,"2020":669,"2021":704,"2022":713,"2023":629,"2024":727,"2025":696,"2026":473},"year":2017,"title":"Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer"},"paper-druker-imatinib-phase1-nejm-2001":{"doi":"10.1056/nejm200104053441401","openalexId":"W2329648702","cited":5279,"byYear":{"2012":251,"2013":237,"2014":184,"2015":180,"2016":163,"2017":163,"2018":133,"2019":138,"2020":132,"2021":130,"2022":149,"2023":128,"2024":106,"2025":107,"2026":79},"year":2001,"title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia"},"paper-body-fatness-iarc-nejm-2016":{"doi":"10.1056/nejmsr1606602","openalexId":"W2510411424","cited":3631,"byYear":{"2015":1,"2016":26,"2017":143,"2018":223,"2019":295,"2020":378,"2021":462,"2022":449,"2023":474,"2024":492,"2025":404,"2026":277},"year":2016,"title":"Body Fatness and Cancer — Viewpoint of the IARC Working Group"},"paper-depmap-tsherniak-cell-2017":{"doi":"10.1016/j.cell.2017.06.010","openalexId":"W2741508285","cited":3600,"byYear":{"2017":26,"2018":108,"2019":196,"2020":294,"2021":386,"2022":406,"2023":470,"2024":629,"2025":712,"2026":373},"year":2017,"title":"Defining a Cancer Dependency Map"},"paper-iris-imatinib-nejm-2003":{"doi":"10.1056/nejmoa022457","openalexId":"W2028959752","cited":3586,"byYear":{"2012":221,"2013":195,"2014":149,"2015":150,"2016":149,"2017":147,"2018":112,"2019":130,"2020":106,"2021":112,"2022":105,"2023":100,"2024":74,"2025":76,"2026":46},"year":2003,"title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia"},"paper-iwai-pdl1-tumour-escape-pnas-2002":{"doi":"10.1073/pnas.192461099","openalexId":"W2063264144","cited":3233,"byYear":{"2012":69,"2013":97,"2014":82,"2015":185,"2016":187,"2017":203,"2018":220,"2019":259,"2020":280,"2021":281,"2022":281,"2023":262,"2024":246,"2025":171,"2026":98},"year":2002,"title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"},"paper-doll-peto-50-year-doctors-bmj-2004":{"doi":"10.1136/bmj.38142.554479.ae","openalexId":"W4292672078","cited":2956,"byYear":{"2012":161,"2013":182,"2014":147,"2015":167,"2016":151,"2017":134,"2018":157,"2019":136,"2020":164,"2021":135,"2022":133,"2023":140,"2024":138,"2025":81,"2026":72},"year":2004,"title":"Mortality in relation to smoking: 50 years' observations on male British doctors"},"paper-checkmate-816-nejm-2022":{"doi":"10.1056/nejmoa2202170","openalexId":"W4223502512","cited":2703,"byYear":{"2022":207,"2023":616,"2024":722,"2025":680,"2026":478},"year":2022,"title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer"},"paper-destiny-breast04-nejm-2022":{"doi":"10.1056/nejmoa2203690","openalexId":"W4281640394","cited":2666,"byYear":{"2017":1,"2022":183,"2023":640,"2024":725,"2025":694,"2026":421},"year":2022,"title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"},"paper-basch-epro-survival-jama-2017":{"doi":"10.1001/jama.2017.7156","openalexId":"W2620925856","cited":2361,"byYear":{"2014":1,"2017":52,"2018":172,"2019":248,"2020":297,"2021":286,"2022":302,"2023":291,"2024":317,"2025":220,"2026":172},"year":2017,"title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment"},"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012":{"doi":"10.1056/nejmoa1110557","openalexId":"W2121743767","cited":2098,"byYear":{"2012":76,"2013":168,"2014":147,"2015":169,"2016":174,"2017":146,"2018":141,"2019":119,"2020":161,"2021":169,"2022":140,"2023":140,"2024":140,"2025":105,"2026":97},"year":2012,"title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis"},"paper-doll-hill-smoking-lung-cancer-bmj-1950":{"doi":"10.1136/bmj.2.4682.739","openalexId":"W1998637589","cited":1991,"byYear":{"2012":66,"2013":74,"2014":65,"2015":70,"2016":69,"2017":73,"2018":69,"2019":66,"2020":79,"2021":51,"2022":85,"2023":44,"2024":51,"2025":69,"2026":36},"year":1950,"title":"Smoking and Carcinoma of the Lung"},"paper-clear-nejm-2021":{"doi":"10.1056/nejmoa2035716","openalexId":"W3131063362","cited":1803,"byYear":{"2020":1,"2021":206,"2022":382,"2023":411,"2024":342,"2025":283,"2026":176},"year":2021,"title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma"},"paper-adaura-nejm-2020":{"doi":"10.1056/nejmoa2027071","openalexId":"W3087210493","cited":1800,"byYear":{"2016":1,"2020":23,"2021":260,"2022":391,"2023":392,"2024":286,"2025":290,"2026":155},"year":2020,"title":"Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer"},"paper-ascent-nejm-2021":{"doi":"10.1056/nejmoa2028485","openalexId":"W3156985612","cited":1641,"byYear":{"2021":68,"2022":224,"2023":305,"2024":356,"2025":394,"2026":293},"year":2021,"title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer"},"paper-cercek-dmmr-rectal-nejm-2022":{"doi":"10.1056/nejmoa2201445","openalexId":"W4281732693","cited":1638,"byYear":{"2014":1,"2017":1,"2021":1,"2022":162,"2023":420,"2024":416,"2025":385,"2026":246},"year":2022,"title":"PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer"},"paper-ino-vate-inotuzumab-all-nejm-2016":{"doi":"10.1056/nejmoa1509277","openalexId":"W2419639370","cited":1404,"byYear":{"2015":2,"2016":23,"2017":118,"2018":127,"2019":169,"2020":166,"2021":145,"2022":161,"2023":137,"2024":130,"2025":131,"2026":88},"year":2016,"title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia"},"paper-admiral-gilteritinib-flt3-nejm-2019":{"doi":"10.1056/nejmoa1902688","openalexId":"W2982353618","cited":1279,"byYear":{"2019":8,"2020":157,"2021":213,"2022":232,"2023":192,"2024":197,"2025":161,"2026":118},"year":2019,"title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML"},"paper-destiny-breast03-nejm-2022":{"doi":"10.1056/nejmoa2115022","openalexId":"W4220964921","cited":1180,"byYear":{"2022":144,"2023":306,"2024":292,"2025":266,"2026":172},"year":2022,"title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer"},"paper-crown-nejm-2020":{"doi":"10.1056/nejmoa2027187","openalexId":"W3101089668","cited":1109,"byYear":{"2019":1,"2020":5,"2021":144,"2022":222,"2023":210,"2024":216,"2025":189,"2026":119},"year":2020,"title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer"},"paper-ev-302-nejm-2024":{"doi":"10.1056/nejmoa2312117","openalexId":"W4392498919","cited":1059,"byYear":{"2021":1,"2024":230,"2025":474,"2026":353},"year":2024,"title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer"},"paper-dynamic-nejm-2022":{"doi":"10.1056/nejmoa2200075","openalexId":"W4281738617","cited":1055,"byYear":{"2021":1,"2022":92,"2023":233,"2024":268,"2025":249,"2026":212},"year":2022,"title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer"},"paper-cll14-venetoclax-obinutuzumab-nejm-2019":{"doi":"10.1056/nejmoa1815281","openalexId":"W2948436219","cited":874,"byYear":{"2013":2,"2019":45,"2020":143,"2021":183,"2022":135,"2023":114,"2024":101,"2025":84,"2026":65},"year":2019,"title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions"},"paper-cartitude-4-cilta-cel-nejm-2023":{"doi":"10.1056/nejmoa2303379","openalexId":"W4379375986","cited":805,"byYear":{"2023":61,"2024":237,"2025":283,"2026":222},"year":2023,"title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma"},"paper-echelon-1-brentuximab-avd-nejm-2018":{"doi":"10.1056/nejmoa1708984","openalexId":"W2775803967","cited":789,"byYear":{"2016":1,"2017":4,"2018":84,"2019":96,"2020":127,"2021":95,"2022":84,"2023":83,"2024":85,"2025":66,"2026":61},"year":2017,"title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma"},"paper-indigo-nejm-2023":{"doi":"10.1056/nejmoa2304194","openalexId":"W4379284101","cited":784,"byYear":{"2015":1,"2022":1,"2023":64,"2024":250,"2025":271,"2026":193},"year":2023,"title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma"},"paper-hpv-vaccine-england-lancet-2021":{"doi":"10.1016/s0140-6736(21)02178-4","openalexId":"W3209481766","cited":781,"byYear":{"2021":12,"2022":153,"2023":155,"2024":183,"2025":168,"2026":109},"year":2021,"title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study"},"paper-alcohol-cancer-burden-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00279-5","openalexId":"W3183035192","cited":696,"byYear":{"2021":28,"2022":86,"2023":138,"2024":206,"2025":142,"2026":96},"year":2021,"title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study"},"paper-detect-a-science-2020":{"doi":"10.1126/science.abb9601","openalexId":"W3020301997","cited":677,"byYear":{"2020":45,"2021":114,"2022":126,"2023":107,"2024":104,"2025":115,"2026":65},"year":2020,"title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention"},"paper-gap70-geriatric-assessment-lancet-2021":{"doi":"10.1016/s0140-6736(21)01789-x","openalexId":"W3209480926","cited":590,"byYear":{"2021":4,"2022":110,"2023":130,"2024":150,"2025":103,"2026":92},"year":2021,"title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study"},"paper-dellphi-301-nejm-2023":{"doi":"10.1056/nejmoa2307980","openalexId":"W4387799038","cited":566,"byYear":{"2023":6,"2024":125,"2025":240,"2026":195},"year":2023,"title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer"},"paper-checkmate-067-10-year-nejm-2025":{"doi":"10.1056/nejmoa2407417","openalexId":"W4402552706","cited":561,"byYear":{"2024":21,"2025":285,"2026":255},"year":2024,"title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma"},"paper-agile-ivosidenib-azacitidine-nejm-2022":{"doi":"10.1056/nejmoa2117344","openalexId":"W4224290890","cited":508,"byYear":{"2019":1,"2022":56,"2023":122,"2024":127,"2025":131,"2026":71},"year":2022,"title":"Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia"},"paper-galaxy-signatera-nat-med-2023":{"doi":"10.1038/s41591-022-02115-4","openalexId":"W4316507345","cited":504,"byYear":{"2021":1,"2022":1,"2023":68,"2024":171,"2025":161,"2026":102},"year":2023,"title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer"},"paper-ibis-i-tamoxifen-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71171-4","openalexId":"W2161387798","cited":466,"byYear":{"2014":1,"2015":36,"2016":44,"2017":41,"2018":43,"2019":37,"2020":44,"2021":48,"2022":38,"2023":47,"2024":36,"2025":35,"2026":15},"year":2014,"title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial"},"paper-capp2-aspirin-lynch-lancet-2020":{"doi":"10.1016/s0140-6736(20)30366-4","openalexId":"W3034846243","cited":427,"byYear":{"2020":20,"2021":56,"2022":64,"2023":88,"2024":63,"2025":79,"2026":56},"year":2020,"title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial"},"paper-codebreak-300-nejm-2023":{"doi":"10.1056/nejmoa2308795","openalexId":"W4387859726","cited":370,"byYear":{"2023":7,"2024":125,"2025":144,"2026":94},"year":2023,"title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C"},"paper-challenge-exercise-nejm-2025":{"doi":"10.1056/nejmoa2502760","openalexId":"W4410927245","cited":330,"byYear":{"2024":1,"2025":101,"2026":228},"year":2025,"title":"Structured Exercise after Adjuvant Chemotherapy for Colon Cancer"},"paper-adriatic-nejm-2024":{"doi":"10.1056/nejmoa2404873","openalexId":"W4402519167","cited":329,"byYear":{"2022":1,"2024":27,"2025":164,"2026":137},"year":2024,"title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer"},"paper-drug-dosing-conundrum-nejm-2021":{"doi":"10.1056/nejmp2109826","openalexId":"W3204811815","cited":290,"byYear":{"2021":3,"2022":46,"2023":76,"2024":75,"2025":55,"2026":35},"year":2021,"title":"The Drug-Dosing Conundrum in Oncology — When Less Is More"},"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024":{"doi":"10.1056/nejmoa2312948","openalexId":"W4400940914","cited":259,"byYear":{"2024":24,"2025":132,"2026":103},"year":2024,"title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults"},"paper-lynch-frameshift-vaccine-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3517","openalexId":"W3035696000","cited":146,"byYear":{"2020":3,"2021":20,"2022":18,"2023":38,"2024":24,"2025":22,"2026":21},"year":2020,"title":"A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial"},"paper-stupp-temozolomide-nejm-2005":{"doi":"10.1056/nejmoa043330","openalexId":"W2096287682","cited":22006,"byYear":{"2012":873,"2013":904,"2014":1020,"2015":1112,"2016":1067,"2017":1154,"2018":1163,"2019":1282,"2020":1483,"2021":1679,"2022":1595,"2023":1591,"2024":1589,"2025":1399,"2026":996},"year":2005,"title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma"},"paper-nlst-nejm-2011":{"doi":"10.1056/nejmoa1102873","openalexId":"W130099911","cited":11212,"byYear":{"2012":376,"2013":498,"2014":529,"2015":607,"2016":596,"2017":593,"2018":724,"2019":767,"2020":934,"2021":981,"2022":960,"2023":1001,"2024":1013,"2025":884,"2026":594},"year":2011,"title":"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening"},"paper-le-mmr-deficiency-pd1-nejm-2015":{"doi":"10.1056/nejmoa1500596","openalexId":"W1940241680","cited":9571,"byYear":{"2013":1,"2014":5,"2015":167,"2016":673,"2017":882,"2018":942,"2019":921,"2020":1168,"2021":1194,"2022":1023,"2023":915,"2024":731,"2025":582,"2026":356},"year":2015,"title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency"},"paper-temel-early-palliative-care-nejm-2010":{"doi":"10.1056/nejmoa1000678","openalexId":"W2147016542","cited":7538,"byYear":{"2012":359,"2013":405,"2014":453,"2015":478,"2016":531,"2017":599,"2018":541,"2019":525,"2020":548,"2021":544,"2022":520,"2023":470,"2024":486,"2025":417,"2026":313},"year":2010,"title":"Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer"},"paper-le-mmr-deficiency-science-2017":{"doi":"10.1126/science.aan6733","openalexId":"W2622499649","cited":6789,"byYear":{"2013":1,"2015":3,"2017":129,"2018":608,"2019":745,"2020":931,"2021":972,"2022":951,"2023":819,"2024":705,"2025":536,"2026":380},"year":2017,"title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade"},"paper-keynote-189-nejm-2018":{"doi":"10.1056/nejmoa1801005","openalexId":"W2796582438","cited":6742,"byYear":{"2013":1,"2015":1,"2016":1,"2017":2,"2018":286,"2019":679,"2020":988,"2021":1093,"2022":924,"2023":848,"2024":853,"2025":651,"2026":402},"year":2018,"title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer"},"paper-maude-ctl019-all-nejm-2014":{"doi":"10.1056/nejmoa1407222","openalexId":"W2118796952","cited":5472,"byYear":{"2012":4,"2013":3,"2014":24,"2015":262,"2016":385,"2017":541,"2018":500,"2019":540,"2020":690,"2021":575,"2022":507,"2023":524,"2024":394,"2025":320,"2026":193},"year":2014,"title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia"},"paper-jaiswal-chip-nejm-2014":{"doi":"10.1056/nejmoa1408617","openalexId":"W2149858388","cited":4868,"byYear":{"2012":3,"2013":1,"2014":6,"2015":150,"2016":242,"2017":303,"2018":357,"2019":392,"2020":468,"2021":534,"2022":553,"2023":543,"2024":515,"2025":448,"2026":342},"year":2014,"title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes"},"paper-pacific-nejm-2017":{"doi":"10.1056/nejmoa1709937","openalexId":"W2753065806","cited":4635,"byYear":{"2013":1,"2014":1,"2017":47,"2018":453,"2019":465,"2020":581,"2021":645,"2022":569,"2023":552,"2024":540,"2025":468,"2026":309},"year":2017,"title":"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer"},"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019":{"doi":"10.1056/nejmoa1804980","openalexId":"W2903062212","cited":4140,"byYear":{"2012":2,"2013":1,"2015":1,"2018":3,"2019":219,"2020":514,"2021":648,"2022":700,"2023":608,"2024":620,"2025":504,"2026":307},"year":2018,"title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma"},"paper-leach-allison-ctla4-blockade-science-1996":{"doi":"10.1126/science.271.5256.1734","openalexId":"W2094366129","cited":3953,"byYear":{"2012":86,"2013":111,"2014":90,"2015":187,"2016":203,"2017":214,"2018":239,"2019":309,"2020":341,"2021":317,"2022":260,"2023":274,"2024":265,"2025":212,"2026":96},"year":1996,"title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade"},"paper-nelson-nejm-2020":{"doi":"10.1056/nejmoa1911793","openalexId":"W3003415550","cited":3640,"byYear":{"2012":1,"2020":282,"2021":503,"2022":551,"2023":613,"2024":610,"2025":635,"2026":438},"year":2020,"title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial"},"paper-minnesota-fobt-nejm-1993":{"doi":"10.1056/nejm199305133281901","openalexId":"W2046686567","cited":3265,"byYear":{"2012":126,"2013":121,"2014":116,"2015":115,"2016":87,"2017":90,"2018":73,"2019":74,"2020":68,"2021":71,"2022":63,"2023":55,"2024":58,"2025":38,"2026":21},"year":1993,"title":"Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood"},"paper-keynote-177-nejm-2020":{"doi":"10.1056/nejmoa2017699","openalexId":"W3110528877","cited":3102,"byYear":{"2012":1,"2020":4,"2021":376,"2022":581,"2023":617,"2024":568,"2025":538,"2026":412},"year":2020,"title":"Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer"},"paper-solo-1-nejm-2018":{"doi":"10.1056/nejmoa1810858","openalexId":"W2897430921","cited":2911,"byYear":{"2013":1,"2017":1,"2018":15,"2019":227,"2020":414,"2021":458,"2022":428,"2023":432,"2024":378,"2025":323,"2026":226},"year":2018,"title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer"},"paper-tcga-pancancer-atlas-cell-2018":{"doi":"10.1016/j.cell.2018.03.022","openalexId":"W2796153844","cited":2775,"byYear":{"2013":1,"2018":71,"2019":199,"2020":371,"2021":433,"2022":409,"2023":390,"2024":365,"2025":305,"2026":228},"year":2018,"title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer"},"paper-katherine-nejm-2019":{"doi":"10.1056/nejmoa1814017","openalexId":"W2902218997","cited":2676,"byYear":{"2017":1,"2018":1,"2019":160,"2020":324,"2021":415,"2022":430,"2023":411,"2024":397,"2025":320,"2026":209},"year":2018,"title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer"},"paper-ostrem-kras-g12c-nature-2013":{"doi":"10.1038/nature12796","openalexId":"W2128339707","cited":2572,"byYear":{"2013":2,"2014":85,"2015":109,"2016":133,"2017":121,"2018":123,"2019":140,"2020":196,"2021":241,"2022":303,"2023":283,"2024":321,"2025":285,"2026":225},"year":2013,"title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions"},"paper-protac-concept-sakamoto-pnas-2001":{"doi":"10.1073/pnas.141230798","openalexId":"W2151683271","cited":2544,"byYear":{"2012":10,"2013":9,"2014":13,"2015":15,"2016":27,"2017":47,"2018":80,"2019":118,"2020":201,"2021":230,"2022":300,"2023":321,"2024":388,"2025":421,"2026":264},"year":2001,"title":"Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation"},"paper-paola-1-nejm-2019":{"doi":"10.1056/nejmoa1911361","openalexId":"W2994977341","cited":2096,"byYear":{"2019":1,"2020":180,"2021":320,"2022":375,"2023":396,"2024":346,"2025":278,"2026":194},"year":2019,"title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer"},"paper-martincorena-somatic-mutations-normal-skin-science-2015":{"doi":"10.1126/science.aaa6806","openalexId":"W1956871134","cited":1867,"byYear":{"2014":2,"2015":34,"2016":122,"2017":158,"2018":150,"2019":191,"2020":218,"2021":216,"2022":205,"2023":175,"2024":166,"2025":143,"2026":85},"year":2015,"title":"High burden and pervasive positive selection of somatic mutations in normal human skin"},"paper-relativity-047-nejm-2022":{"doi":"10.1056/nejmoa2109970","openalexId":"W4206239577","cited":1861,"byYear":{"2022":274,"2023":415,"2024":493,"2025":400,"2026":279},"year":2022,"title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma"},"paper-stampede-abiraterone-nejm-2017":{"doi":"10.1056/nejmoa1702900","openalexId":"W2620746860","cited":1803,"byYear":{"2015":1,"2016":1,"2017":95,"2018":240,"2019":234,"2020":225,"2021":221,"2022":194,"2023":175,"2024":164,"2025":162,"2026":87},"year":2017,"title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy"},"paper-olympia-nejm-2021":{"doi":"10.1056/nejmoa2105215","openalexId":"W3165576985","cited":1730,"byYear":{"2021":90,"2022":330,"2023":377,"2024":383,"2025":341,"2026":206},"year":2021,"title":"Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer"},"paper-hpv-vaccine-sweden-nejm-2020":{"doi":"10.1056/nejmoa1917338","openalexId":"W3090300247","cited":1502,"byYear":{"2020":13,"2021":269,"2022":254,"2023":277,"2024":254,"2025":263,"2026":167},"year":2020,"title":"HPV Vaccination and the Risk of Invasive Cervical Cancer"},"paper-brca-risk-reducing-surgery-jama-2010":{"doi":"10.1001/jama.2010.1237","openalexId":"W2117576401","cited":1497,"byYear":{"2012":80,"2013":82,"2014":103,"2015":91,"2016":116,"2017":126,"2018":102,"2019":120,"2020":110,"2021":95,"2022":63,"2023":98,"2024":92,"2025":68,"2026":52},"year":2010,"title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality"},"paper-majestec-1-teclistamab-nejm-2022":{"doi":"10.1056/nejmoa2203478","openalexId":"W4282033105","cited":1219,"byYear":{"2013":1,"2022":39,"2023":236,"2024":330,"2025":343,"2026":267},"year":2022,"title":"Teclistamab in Relapsed or Refractory Multiple Myeloma"},"paper-keynote-522-nejm-2022":{"doi":"10.1056/nejmoa2112651","openalexId":"W4210957314","cited":1209,"byYear":{"2022":157,"2023":268,"2024":315,"2025":270,"2026":199},"year":2022,"title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer"},"paper-maia-daratumumab-rd-nejm-2019":{"doi":"10.1056/nejmoa1817249","openalexId":"W2947874495","cited":1014,"byYear":{"2012":1,"2018":1,"2019":39,"2020":194,"2021":209,"2022":146,"2023":130,"2024":110,"2025":110,"2026":70},"year":2019,"title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma"},"paper-murano-venetoclax-rituximab-nejm-2018":{"doi":"10.1056/nejmoa1713976","openalexId":"W2792666902","cited":932,"byYear":{"2013":1,"2017":1,"2018":52,"2019":133,"2020":132,"2021":144,"2022":123,"2023":111,"2024":104,"2025":78,"2026":52},"year":2018,"title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia"},"paper-polarix-polatuzumab-rchp-nejm-2022":{"doi":"10.1056/nejmoa2115304","openalexId":"W4200197309","cited":917,"byYear":{"2020":1,"2022":84,"2023":164,"2024":205,"2025":259,"2026":204},"year":2021,"title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma"},"paper-hpv-self-sampling-bmj-2018":{"doi":"10.1136/bmj.k4823","openalexId":"W2902810541","cited":899,"byYear":{"2019":41,"2020":97,"2021":106,"2022":130,"2023":145,"2024":155,"2025":142,"2026":82},"year":2018,"title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses"},"paper-ruby-nejm-2023":{"doi":"10.1056/nejmoa2216334","openalexId":"W4360991857","cited":850,"byYear":{"2021":1,"2023":117,"2024":283,"2025":295,"2026":154},"year":2023,"title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer"},"paper-nordicc-nejm-2022":{"doi":"10.1056/nejmoa2208375","openalexId":"W4303940405","cited":812,"byYear":{"2012":1,"2022":10,"2023":184,"2024":255,"2025":228,"2026":133},"year":2022,"title":"Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death"},"paper-keynote-564-nejm-2021":{"doi":"10.1056/nejmoa2106391","openalexId":"W3196207248","cited":781,"byYear":{"2021":26,"2022":200,"2023":176,"2024":152,"2025":136,"2026":89},"year":2021,"title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma"},"paper-karmma-3-ide-cel-nejm-2023":{"doi":"10.1056/nejmoa2213614","openalexId":"W4319812103","cited":759,"byYear":{"2013":1,"2023":102,"2024":248,"2025":236,"2026":168},"year":2023,"title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma"},"paper-rohaas-til-vs-ipilimumab-nejm-2022":{"doi":"10.1056/nejmoa2210233","openalexId":"W4311584464","cited":569,"byYear":{"2022":6,"2023":95,"2024":164,"2025":189,"2026":115},"year":2022,"title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma"},"paper-perseus-dara-vrd-transplant-nejm-2024":{"doi":"10.1056/nejmoa2312054","openalexId":"W4389606680","cited":563,"byYear":{"2023":3,"2024":150,"2025":253,"2026":156},"year":2023,"title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma"},"paper-masai-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00298-x","openalexId":"W4385448527","cited":560,"byYear":{"2022":1,"2023":32,"2024":169,"2025":207,"2026":151},"year":2023,"title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study"},"paper-predimed-breast-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.4838","openalexId":"W2155215362","cited":521,"byYear":{"2015":6,"2016":31,"2017":42,"2018":59,"2019":45,"2020":49,"2021":74,"2022":52,"2023":55,"2024":43,"2025":35,"2026":28},"year":2015,"title":"Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial"},"paper-nadina-nejm-2024":{"doi":"10.1056/nejmoa2402604","openalexId":"W4399274678","cited":518,"byYear":{"2024":68,"2025":267,"2026":183},"year":2024,"title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma"},"paper-niche-2-nejm-2024":{"doi":"10.1056/nejmoa2400634","openalexId":"W4399369796","cited":456,"byYear":{"2024":61,"2025":207,"2026":188},"year":2024,"title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer"},"paper-mariposa-nejm-2024":{"doi":"10.1056/nejmoa2403614","openalexId":"W4400029774","cited":441,"byYear":{"2023":1,"2024":39,"2025":236,"2026":165},"year":2024,"title":"Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC"},"paper-prasad-surrogate-endpoints-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.2829","openalexId":"W1570249624","cited":403,"byYear":{"2013":1,"2015":7,"2016":24,"2017":32,"2018":38,"2019":40,"2020":27,"2021":38,"2022":38,"2023":43,"2024":50,"2025":33,"2026":31},"year":2015,"title":"The Strength of Association Between Surrogate End Points and Survival in Oncology"},"paper-niagara-nejm-2024":{"doi":"10.1056/nejmoa2408154","openalexId":"W4402552345","cited":393,"byYear":{"2024":14,"2025":192,"2026":187},"year":2024,"title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer"},"paper-pathfinder-lancet-2023":{"doi":"10.1016/s0140-6736(23)01700-2","openalexId":"W4387381160","cited":389,"byYear":{"2023":6,"2024":116,"2025":147,"2026":120},"year":2023,"title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study"},"paper-natalee-nejm-2024":{"doi":"10.1056/nejmoa2305488","openalexId":"W4392977246","cited":389,"byYear":{"2023":2,"2024":78,"2025":196,"2026":113},"year":2024,"title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer"},"paper-reproducibility-project-cancer-biology-elife-2021":{"doi":"10.7554/elife.71601","openalexId":"W4200247206","cited":386,"byYear":{"2021":8,"2022":72,"2023":117,"2024":69,"2025":74,"2026":45},"year":2021,"title":"Investigating the replicability of preclinical cancer biology"},"paper-swog-s1826-nivolumab-avd-nejm-2024":{"doi":"10.1056/nejmoa2405888","openalexId":"W4403462752","cited":242,"byYear":{"2020":1,"2024":9,"2025":121,"2026":111},"year":2024,"title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma"},"paper-nhs-galleri-design-cancers-2022":{"doi":"10.3390/cancers14194818","openalexId":"W4303613649","cited":182,"byYear":{"2022":3,"2023":32,"2024":58,"2025":51,"2026":38},"year":2022,"title":"Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial"},"paper-hallmarks-of-cancer-cell-2000":{"doi":"10.1016/s0092-8674(00)81683-9","openalexId":"W2034269086","cited":28704,"byYear":{"2012":1477,"2013":1398,"2014":1404,"2015":1343,"2016":1193,"2017":1156,"2018":1055,"2019":1063,"2020":1196,"2021":1253,"2022":1160,"2023":1007,"2024":964,"2025":826,"2026":380},"year":2000,"title":"The Hallmarks of Cancer"},"paper-topalian-anti-pd1-nejm-2012":{"doi":"10.1056/nejmoa1200690","openalexId":"W2160834915","cited":12808,"byYear":{"2012":139,"2013":631,"2014":816,"2015":1064,"2016":1206,"2017":1245,"2018":1075,"2019":1061,"2020":1200,"2021":985,"2022":881,"2023":856,"2024":702,"2025":565,"2026":352},"year":2012,"title":"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer"},"paper-zuma-1-axi-cel-nejm-2017":{"doi":"10.1056/nejmoa1707447","openalexId":"W2773804840","cited":6075,"byYear":{"2012":2,"2013":2,"2016":2,"2017":4,"2018":264,"2019":483,"2020":715,"2021":859,"2022":903,"2023":800,"2024":804,"2025":734,"2026":484},"year":2017,"title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma"},"paper-viale-a-venetoclax-azacitidine-nejm-2020":{"doi":"10.1056/nejmoa2012971","openalexId":"W3048827006","cited":2892,"byYear":{"2014":1,"2019":2,"2020":69,"2021":366,"2022":459,"2023":541,"2024":544,"2025":541,"2026":359},"year":2020,"title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia"},"paper-vision-nejm-2021":{"doi":"10.1056/nejmoa2107322","openalexId":"W3176208875","cited":2797,"byYear":{"2012":1,"2014":1,"2021":109,"2022":390,"2023":519,"2024":594,"2025":621,"2026":561},"year":2021,"title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer"},"paper-tracerx-100-nejm-2017":{"doi":"10.1056/nejmoa1616288","openalexId":"W2609243345","cited":2490,"byYear":{"2016":1,"2017":89,"2018":237,"2019":288,"2020":359,"2021":357,"2022":342,"2023":268,"2024":234,"2025":179,"2026":130},"year":2017,"title":"Tracking the Evolution of Non–Small-Cell Lung Cancer"},"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020":{"doi":"10.1056/nejmoa1914347","openalexId":"W3014583893","cited":1866,"byYear":{"2012":1,"2020":81,"2021":328,"2022":370,"2023":330,"2024":331,"2025":247,"2026":172},"year":2020,"title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma"},"paper-zuma-7-axi-cel-second-line-nejm-2022":{"doi":"10.1056/nejmoa2116133","openalexId":"W4200201081","cited":1599,"byYear":{"2013":1,"2021":1,"2022":216,"2023":354,"2024":411,"2025":384,"2026":230},"year":2021,"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma"},"paper-unger-trial-participation-barriers-jnci-2019":{"doi":"10.1093/jnci/djy221","openalexId":"W2915663023","cited":578,"byYear":{"2019":17,"2020":46,"2021":73,"2022":83,"2023":82,"2024":114,"2025":92,"2026":70},"year":2018,"title":"Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation"}},"missing":["paper-cercek-dostarlimab-rectal-nejm-2022","paper-tracerx-evolution-nature-2023"]}